Eradication Rate Between 1- and 2-Week Helicobacter Pylori Eradication Therapy
NCT ID: NCT02487511
Last Updated: 2017-06-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
387 participants
INTERVENTIONAL
2015-08-01
2017-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to investigate which duration would be better for eradication of HP. The study design is a randomized controlled trial. The patients were randomly assigned to 7 days or 14 days treatment groups. Primary endpoint was the eradication rate of PPI based triple therapy. Secondary endpoints were to compare the rate of drug compliance and side effects in both groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection
NCT02483715
Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection
NCT02711176
15-day Sequential Therapy for Helicobacter Pylori Infection in Korea
NCT01887249
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication
NCT00841854
10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication
NCT03134378
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective of the study is to investigate whether treatment duration would affect the eradication rate of HP as a PPI based triple therapy (1st line therapy) and a bismuth-based quadruple therapy (2nd line therapy).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
14 days
14 days treatment regimen
Duration of HP therapy
the comparison of HP eradication rate between 7 days and 14 days
7 days
7 days treatment regimen
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Duration of HP therapy
the comparison of HP eradication rate between 7 days and 14 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Early gastric cancer
* Gastric mucosa-associated lymphoid tissue lymphoma
Exclusion Criteria
* liver cirrhosis
* chronic kidney disease
* pregnancy
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St.Paul's Hospital, Korea
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
JUNG HWAN OH
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JUNG HWAN Oh, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
the Catholic Univerisity of Korea
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Catholic University of Korea
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kim TH, Park JM, Cheung DY, Oh JH. Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial. J Korean Med Sci. 2020 Feb 10;35(5):e33. doi: 10.3346/jkms.2020.35.e33.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HPTX Duration
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.